Roberto Iacovelli
@driacovelli
Associate Profesor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome, Italy. Focused on GU cancers. Husband & father of 2 kids.
ID: 1344629696139554818
31-12-2020 13:01:25
363 Tweet
591 Followers
229 Following
The ESMO - Eur. Oncology guidlines make a clear distinction between papillary and other ‘non-clear cell’ renal cancers. Mixing these together has hampered new treatments. Sarcomatoid needs upfront PD1 combos. Other subgroups (chromaphobe etc) need more data ow.ly/nZA050RP77l
🥳 This paper has been selected as the Journal Title Story in Cancers MDPI 📖 The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)—What Future Prospects Are There for Its Use in Clinical Practice? ✍️ by Prof. Roberto Iacovelli et al 🔗 Link here👉 mdpi.com/2072-6694/16/3…
My full support for G Curigliano MD PhD for the ESMO presidential election. We hope for an Italian ESMO president and Giuseppe is the right person! esmo.org/about-esmo/how…
📢The next days are so important for our Society ESMO - Eur. Oncology. New president will be elected, and two👫 great candidates are in the runoff to make #ESMO greater. My preference✅️ is for G Curigliano MD PhD. I know its value, and I am sure he will support ESMO's growth in the coming years.
My preference for ESMO - Eur. Oncology Presidency is for G Curigliano MD PhD - Roberto Iacovelli Harvard Medical School oncodaily.com/73042.html #Cancer #ESMO #OncoDaily #Oncology
Kudos to Shilpa Gupta for an outstanding presentation! Her insights are incredibly valuable for improving patient care with EV pembro. #Leadership Shilpa Gupta OncoAlert OncoDaily associazionepalinuro Bladder Cancer Advocacy Network World Bladder Cancer Patient Coalition Petros Grivas Roberto Iacovelli AIOM
G Curigliano MD PhD sarà il Presidente dell’ESMO (ESMO - Eur. Oncology) per il biennio 2027-2028. Da #AIOM un grandissimo augurio di buon lavoro al prof. Curigliano. Leggi di più al link: medinews.it/comunicati/esm… Francesco Perrone Massimo Di Maio saverio cinieri rossanaberardi Mauro Boldrini
Great honour to have TIDE-A commented by Laurence Albiges Tom Powles and Dr Wells on European Urology. Timing, perception of toxicity & QoL evaluation after TKI interruption are some issues highlited. 1st step has done, next are awaited soon. Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Giuseppe Procopio Cristiane D Bergerot
📢 Nuova possibilità di cura per pazienti affetti da tumore vescicale muscolo infiltrante eleggibili a chirurgia. Prima evidenza di come l'immunoterapia ⬆️ la sopravvivenza insieme alla chemioterapia! ✅️ astrazeneca.com/media-centre/p… associazionepalinuro
#TiNivo2 results are out —adding PD1 inhibitor nivolumab simply does not help after rechallenge /progression on prior immunotherapy. Time to follow level 1 evidence! PRNEWS Targeted Oncology OncLive.com KidneyCAN Kidney Cancer Uromigos Oncology Brothers —implications beyond renal cancer ?
📢L'Oncologia Medica del Gemelli di Roma è il 1️⃣ centro europeo 🇪🇺a poter fornire la terapia adiuvante nel tumore renale con immunoterapia +/- un💉 vaccino a mRNA 🧬che rende concrete le possibilità di personalizzazione delle cure. Fondazione AIRC per la ricerca sul cancro Corriere.it Salute ANSA Salute & Benessere Università Cattolica
I am so proud of being part of this achievement in #renalcancer and so proud of my team & Chiara helping me in enrolling and managing patients. Really committed to offering the best opportunities and improving research in kidney cancer. Università Cattolica Kidney Cancer ANSA Salute & Benessere
Just in Annals of Oncology 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 UroToday.com OncoAlert KidneyCAN Huntsman Cancer Institute
